The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.

The present invention provides a process for the production of a microbial oil comprising culturing a micro-organism in a two stage fermentation process where, in a last stage that precedes the end of fermentation, the carbon source is: consumed by the micro-organisms at a rate greater than it is added to the medium; added at a rate #0.30 M carbon/kg medium; or is rate limiting on the growth of the micro-organism. The micro-organisms thus have the carbon source restricted so that they preferentially metabolise fats or lipids other than arachidonic acid (ARA), so increasing the proportion of ARA in the cells. A microbial oil is then recovered from the micro-organism, using hexane as a solvent, that has at least 50% ARA and at least 90% triglycerides.

The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

The present invention provides a composition for treating or preventing corneal endothelial symptoms, disorders, or diseases that are attributed to TGF- signaling in corneal endothelial cells. Provided by the present invention is a composition that includes a compound and that is for treating or preventing endothelial symptoms, disorders, or diseases, wherein, when the compound comes into contact with immortalized cells of Fuchs' corneal endothelial dystrophy, (i) said immortalized cells exhibit a cell survival rate (%) of approximately 90% or more after being cultured for 24-28 hours in Dulbecco's modified Eagle medium (DMEM)+2% fetal bovine serum (FBS)+1% penicillin/streptomycin (P/S), and (ii) the ratio of caspase 3/7 activity (%) in the presence of TGF- with respect to said cellular survival rate (%) is at most 0.8 after being cultured for 24-28 hours in Dulbecco's modified Eagle medium (DMEM)+2% fetal bovine serum (FBS)+1% penicillin/streptomycin (P/S).

Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

The present disclosure relates to methods for treating type 1 diabetes (T1D) using a glucagon receptor blocking agent. More specifically, the present disclosure relates to methods for treating T1D using substantially lower doses of insulin supplementation, or even in the absence of insulin supplementation, using antigen binding and antagonizing proteins, e.g., fully human antibodies that specifically bind to and antagonize the function of the human glucagon receptor.

Compositions and methods for influencing the recovery of an animal from the effects of strenuous physical activity. The compositions generally comprise about 4% to 6% readily absorbable carbohydrate; about 10% to 30% maltodextrins; about 20% to 50% starch, for a total of about 40% to 80% carbohydrate; about 20% to about 40% protein; and optionally one or more antioxidants. The methods generally comprise administering the composition to an animal within the period from about 120 minutes before initiation of or 120 minutes after completion of the physical activity.

Provided are injectable, hyaluronic acid-based hydrogel compositions including conjugated vitamins.

There are disclosed compositions and methods for treating obesity using 5-D-fructose dehydrogenase. Other embodiments are also described.

This invention relates to a process for producing solid formulations. These solid formulations comprise therapeutically active or nutritious plant extracts, which are known for being bad-tasting. These new solid formulation are neutral in taste. Furthermore the present invention relate to these solid formulations as well as to their use in the production of food, feed, nutritional supplement and personal care products.